Lartruvo (olaratumab)

NOTICE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.

DESCRIPTION

Lartruvo (olaratumab) received FDA approval in 2016 through the accelerated approval process. Lartruvo, in combination with doxorubicin, is indicated for the treatment of adult patients with soft tissue sarcoma not amenable to curative treatment. Following the accelerated approval, a Phase 3 clinical trial was required to confirm clinical benefit.

POLICY

I. Lartruvo (olaratumab) is considered **investigational** for all indications, including the treatment of soft tissue sarcoma, due to insufficient evidence to demonstrate clinical efficacy.

CLINICAL RATIONALE

ANNOUCE, the Phase 3 clinical trial for Lartruvo, was completed in December 2018. Lartruvo with doxorubicin did not meet the primary endpoint of improved survival as compared to placebo plus

doxorubicin. In response to the results of the trial, the FDA has recommended that Lartruvo not be initiated in new patients outside of an investigational study.

PROCEDURES AND BILLING CODES

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.

- C9485 Injection, olaratumab
- J9285 Injection, olaratumab, 10mg

REFERENCES

POLICY HISTORY

Policy #: 05.02.66
Policy Creation: February 2019
Reviewed:
Revised:
Current Effective Date: June 1, 2019